Please Wait...

BioClinica eClinical Suite Chosen by Top BioTech Firm

– Integrated Clinical Technology Portfolio to Maximize Efficiency and Manageability for Pivotal Study –

February 28, 2012

February 28, 2012.  NEWTOWN, PA – BioClinica®, Inc., (NASDAQ: BIOC), a global provider of clinical trial management solutions, today announced that Amarin Corporation plc has chosen the eClinical suite from BioClinica to capture and manage clinical data for their Phase IIIb cardiology clinical trial, including: electronic data capture (EDC) and data management, interactive response technology (IRT/IVR/IWR), and clinical trial management (CTMS) solutions. Amarin Corporation is a late-stage biopharmaceutical company focused on the treatment of cardiovascular disease. The study is planned to involve approximately 300 sites and 8,000 patients globally.

BioClinica's Trident IWR and EDC systems were selected based on BioClinica's advanced technology portfolio, experience with large global trials; and cardiology expertise. BioClinica was able to build and deploy the study within 4 weeks.

"We are pleased that Amarin's clinical development team selected an integrated solution from BioClinica that will seamlessly share essential clinical data while streamlining their clinical data and site management processes," said Peter Benton, BioClinica's President of eClinical Solutions. "In the last two quarters we have seen sponsors and CROs significantly increase their interest and investment in solutions that are not only "best-in-class" but also reduce the cost and hassle of unifying their clinical data to both manage their trials as well as readying their data for analysis."

About Bioclinica
Bioclinica is organized into three business segments so that we can provide expert service and multifaceted technologies. Our Medical Imaging & Biomarkers segment includes an Imaging Core Lab, a Cardiovascular Safety division, and a Molecular Marker Laboratory. Our eHealth segment comprises eClinical Solutions, Randomization & Trial Supply Management, Safety & Regulatory Solutions, and Financial Lifecycle Solutions. Under the Global Clinical Research segment, we offer a network of research sites, patient recruitment, and a Post-Approval Research division. The Company serves more than 400 pharmaceutical, biotechnology and device organizations – including all of the top 20 – through a network of offices in the U.S., Europe and Asia.

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Bioclinica is organized into three business segments so that we can provide expert service and multifaceted technologies. Our Medical Imaging & Biomarkers segment includes an Imaging Core Lab, a Cardiovascular Safety division, and a Molecular Marker Laboratory. Our eHealth segment comprises eClinical Solutions, Randomization & Trial Supply Management, Safety & Regulatory Solutions, and Financial Lifecycle Solutions. Under the Global Clinical Research segment, we offer a network of research sites, patient recruitment, and a Post-Approval Research division.

"Mud run" 1 obstacle in vaccine trials w elderly. Here R 5 more & how to conquer by Dr. Craig Curtis… https://t.co/vIk4B2Howd
bioclinica (7 hours ago)
What's new in tech for ICH E6 R2 reqs for quality and #RBM? https://t.co/xsmNm8d35o #Pharma
bioclinica (10 hours ago)
Vaccine clinical trials: Boost senior participation following simple advice from Dr. Craig Curtis… https://t.co/OuTKyu0DPT
bioclinica (11 hours ago)
RT @ElisendaGendra: Decision on #EMA Relocation Set for November, Council Agrees on Bidding Procedure via @RAPSorg https://t.co/a42Eszg81o…
bioclinica (Yesterday)
@Xtalks Looking forward to tomorrow's webinar on site payments!
bioclinica (Yesterday)
Conducting Lymphoma ClinicalTrials? Lugano 2014 criteria for assessing FDG-PET/CT. An operational appch https://t.co/x5bdpI8jUI
bioclinica (Yesterday)

Latest Blogs: